Literature DB >> 19679474

Molecular modeling studies to predict the possible binding modes of endomorphin analogs in mu opioid receptor.

Xin Liu1, Ming Kai, Lian Jin, Rui Wang.   

Abstract

The molecular docking of a series of endomorphin analog with the mu opioid receptor was performed. The successive molecular dynamics of several proposed ligand-receptor complexes inserted into the phospholipid bilayer were carried out to optimize the complex and explore the conformational changes. Meaningful differences of their binding modes were detected and the involvement of some essential residues in ligand binding was also identified. Our proposed ligand-receptor model is in good agreement with previous site-directed mutagenesis experiments.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19679474     DOI: 10.1016/j.bmcl.2009.07.121

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  4 in total

1.  Structural basis for μ-opioid receptor binding and activation.

Authors:  Adrian W R Serohijos; Shuangye Yin; Feng Ding; Josee Gauthier; Dustin G Gibson; William Maixner; Nikolay V Dokholyan; Luda Diatchenko
Journal:  Structure       Date:  2011-11-09       Impact factor: 5.006

2.  Synthesis, pharmacological evaluation and conformational investigation of endomorphin-2 hybrid analogues.

Authors:  Giordano Lesma; Severo Salvadori; Francesco Airaghi; Engin Bojnik; Anna Borsodi; Teresa Recca; Alessandro Sacchetti; Gianfranco Balboni; Alessandra Silvani
Journal:  Mol Divers       Date:  2012-11-04       Impact factor: 2.943

3.  Consensus 3D model of μ-opioid receptor ligand efficacy based on a quantitative Conformationally Sampled Pharmacophore.

Authors:  Jihyun Shim; Andrew Coop; Alexander D MacKerell
Journal:  J Phys Chem B       Date:  2011-05-12       Impact factor: 2.991

Review 4.  Recent advances on the δ opioid receptor: from trafficking to function.

Authors:  Louis Gendron; Nitish Mittal; Hélène Beaudry; Wendy Walwyn
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.